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Antibiotic Prevention of Acute
Exacerbations of COPD
Richard P. Wenzel, M.D., Alpha A. Fowler III, M.D.,
and Michael B. Edmond, M.D., M.P.H., M.P.A.
This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion
of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies,
the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines,
if they exist, are presented. The article ends with the authors’ clinical recommendations.
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A 55-year-old man presents with a history of recurrent exacerbations of chronic obstructive pulmonary disease (COPD) during the past year. These episodes were characterized by increased shortness of breath, cough, and sputum production. The diagnosis of COPD was made 2 years previously. Pulmonary-function testing then
revealed a forced expiratory volume in 1 second (FEV1) of 50% of the predicted value
after bronchodilator inhalation, with a ratio of FEV1 to forced vital capacity (FVC) of
60%. The patient had a 30-pack-year smoking history but stopped smoking after
chronic lung disease was diagnosed. On the current visit, he is afebrile and has a
resting pulse of 84 beats per minute. A careful review confirms that he is knowledgeable about proper inhaler use and that he is compliant with his medications, which
include maintenance therapy with salmeterol and fluticasone as well as albuterol
plus ipratropium as needed for intermittent therapy for increased dyspnea. His physician recommends the use of azithromycin at a dose of 250 mg daily to reduce the
frequency of acute exacerbations.

The Cl inic a l Probl em
An estimated 24 million persons in the United States have COPD on the basis of
lung-function testing.1 Globally, COPD is the fourth leading cause of death,2 and in
the United States it is the third most common cause of death and chronic complications.3
The average person with COPD has one to two acute exacerbations each year,
with wide variation from patient to patient.4 In 2000 in the United States, 726,000
patients were hospitalized with acute exacerbations of COPD.1 During an acute exacerbation, antibiotics are generally administered for 5 to 10 days,5 creating a national burden of 120 million to 480 million antibiotic-days annually. The median
hospital stay per exacerbation has been estimated at 9 days.6 In a 2007 Canadian
study, the median cost of a hospital stay after an acute exacerbation of COPD was
$9,557 (Canadian dollars).7
Acute exacerbations of COPD requiring hospitalization are associated with a
30-day rate of death from any cause of 4 to 30%.6 A study in Sweden showed an
all-cause mortality of 26% at 30 days and of 69% at 3 years.8 Acute exacerbations
also accelerate the progressive decline in lung function associated with COPD.
Overall, the FEV1 falls by approximately 33 ml per year in patients with COPD.4
Each acute exacerbation increases the rate of decline by an additional 2 ml per year4
and by up to 7 ml per year in smokers.6
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Pathoph ysiol o gy a nd Effec t
of Ther a py
COPD is characterized by chronic airway inflammation resulting in increased mucus production
and airway ciliary malfunction. The inflammatory
process leads to destruction of respiratory bronchioles, parenchymal loss, and thickening of the
vascular wall.9,10 With progressive limitation of
airflow and decrements of both oxygen and carbon dioxide exchange, elevated pulmonary-artery
pressures and eventually right ventricular hypertrophy and right heart failure (cor pulmonale) develop in some patients.11 Expiratory airflow obstruction is a prominent clinical feature and the
key measure of disease progression.
Exacerbations of COPD have been shown to
coincide with acute respiratory viral infections,
including those with picornaviruses, influenza
virus, and respiratory syncytial virus.12 At the
same time, the sputum of patients with COPD is
colonized with bacteria, often with newly acquired
strains of known pathogens such as Streptococcus
pneumoniae, Haemophilus influenzae, and Moraxella
catarrhalis.13 Lines of evidence linking bacteria to
acute exacerbations include the finding of new
bacterial strains in 33% of patients seen in clinics
for exacerbations,13 a correlation between bacterial
colonization of lower airways and elevated levels
of inflammatory mediators (e.g., tumor necrosis
factor α, interleukin-6, and interleukin-8),14-16 a
correlation between substantial bacterial infection
of small airways and acute exacerbations,17-20 and
improved outcomes after antibiotic treatment.21
Members of the macrolide class of antibiotics
— including erythromycin, clarithromycin, and
azithromycin — inhibit bacterial RNA-directed
protein assembly by binding to the 50S subunit
of bacterial ribosomes.22 In addition to their antimicrobial efficacy, macrolides have been shown
to have antiinflammatory and immune-modulating effects.23 It has been shown that these
drugs decrease the production of cytokines in
the lungs24 (Fig. 1). In most clinical trials, 90%
or more of patients with acute exacerbations of
COPD who were treated with macrolides had
increased rates of early clinical response.25

that daily administration of 250 mg of azithromycin for 1 year would reduce the frequency of
acute exacerbations of COPD. Among the participants, 570 received azithromycin and 572 received placebo. Among patients in the azithromycin group, the median time to the first acute
exacerbation was increased by 92 days (from 174
days in the placebo group to 266 days in the
azithromycin group). The frequency of exacerbations was 1.48 per year in the azithromycin group
versus 1.83 in the placebo group (hazard ratio in
the azithromycin group, 0.73; 95% confidence
interval [CI], 0.63 to 0.84; P<0.001). Quality of
life, as measured by the St. George’s Respiratory
Questionnaire, improved to a greater degree in
the azithromycin group than in the placebo
group. There was no significant difference in
overall mortality between the groups. Patients
with risk factors for adverse effects of azithromycin were excluded from the trial. Potential participants were not enrolled if they had known
hearing impairment (as documented on audiometric testing) or a corrected QT (QTc) interval
of more than 450 msec or if they were using other medications (except amiodarone) that could
prolong the QTc interval. Patients with a resting
pulse rate of more than 100 beats per minute
were also excluded.
In another long-term, placebo-controlled clinical trial examining macrolide antibiotics in the
prevention of acute exacerbations of COPD involving 109 patients, erythromycin was the active
drug, given at a dose of 250 mg twice daily for
1 year.27 The primary outcome was the number
of moderate or severe exacerbations (as treated
with systemic glucocorticoids, antibiotics, or hospitalization). The rate ratio for exacerbations in
the erythromycin group was 0.65 (95% CI, 0.49
to 0.86; P = 0.003).

Cl inic a l Use

All patients with the diagnosis of COPD should
be treated according to the recommendations in
current guidelines. Recent updates to the American College of Physicians guidelines28 and the
Global Initiative for Chronic Obstructive Lung
Disease (known as GOLD) report29 make broadly
similar recommendations for COPD management.
Cl inic a l E v idence
These include smoking cessation, enrollment in
A recent large clinical trial by Albert et al.26 in- a pulmonary rehabilitation program, and the use
volving 1142 volunteers examined the hypothesis of evidence-based medications, including longn engl j med 367;4
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Figure 1. Activation of the Immune Response by Bacteria or Viruses within the Airway of Patients with COPD.
Pathogens in the luminal airway induce the secretion of chemokines (tumor necrosis factor α, interleukin-6, and interleukin-8) and leukotrienes by both macrophages and airway epithelium. This process triggers vascular adhesion
and migration of neutrophils into the wall of the airway and into airway lumens. Serine proteases and other mediators that
are2 secreted by
migrating neutrophils both inflame the airways and destroy bronchial epithelium, leading
6/28/12
Draft
to clinical exacerbation. Azithromycin inhibits bacteria and down-regulates certain key parts of the immune reWenzel
sponse, thus providing a protective activity when used prophylactically.
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acting inhaled beta-agonists, long-acting inhaled
anticholinergic agents, and inhaled glucocorticoids. It is also important to assess and emphasize proper inhaler use and compliance with all
aspects of therapy.
A patient who continues to have frequent acute
exacerbations despite guidelines-based treatment
is a potential candidate for prophylactic use of
azithromycin (Table 1). In our view, a patient
should have had at least two episodes of acute
exacerbation in the previous year to be considered for such therapy, both to provide a baseline
against which to assess clinical response and to
limit overuse of azithromycin in the wider population of patients with COPD. Patients with any
of the exclusion criteria that were used in the
trial by Albert et al.26 should not take azithromycin. The resting pulse rate should be less than
100 beats per minute, and the patient should
undergo electrocardiography to rule out a QTc of
more than 450 msec and formal audiography to
exclude any hearing deficit. In addition, the patient should not be taking any drug that is known
to increase the QTc interval. Furthermore, since
azithromycin is an inhibitor of the cytochrome
P-450 enzyme CYP3A4, it should not be used if
the patient is taking any drug that is metabolized by that enzyme.
The dose of azithromycin that was used in the
clinical trial was 250 mg per day. In earlier pharmacokinetics studies of azithromycin, Foulds et
al.30 found that after the administration of 250 mg
of azithromycin, the usual serum peak level was
0.4 μg per milliliter. However, with repeated daily
administration, lung-tissue levels were usually 75
times as high, and tissue levels persisted even after
serum levels declined. Furthermore, in a murine
model of lung infection, Retsema et al. found that
azithromycin was bactericidal and that the effect
correlated with lung-tissue levels of the drug.31 Tissue levels of azithromycin are sufficient for a bactericidal effect after administration three times a
week or a larger weekly dose alone. In addition,
macrolide prophylaxis has been used successfully
in other conditions in regimens ranging from once
daily to once weekly to three times weekly (see
below). Thus, we do not think that daily administration is necessary, and even though there are no
specific data to support this approach, we favor a
regimen consisting of 250 mg administered on
Monday, Wednesday, and Friday.
Dose adjustment is not needed for renal dysn engl j med 367;4

Table 1. Proposed Criteria for Selecting Patients with COPD for Long-Term
Azithromycin Prophylaxis.
History of COPD with ≥2 acute exacerbations in the previous year
Compliance with current drug regimen and proper use of inhaler
Pulse <100 beats per minute
Corrected QT interval of <450 msec on electrocardiography
Aminotransferase levels <3 times the upper limit of normal range
No use of drugs known to cause QT prolongation
No decrement in hearing on formal audiography
No allergy to macrolides
Sputum culture negative for mycobacteria
No high baseline risk of cardiovascular disease

function. However, because macrolides are metabolized in the liver, we suggest not using
azithromycin if the patient has moderate or severe liver disease, as indicated by serum aminotransferase levels of more than three times the
upper limit of the normal range. This suggestion
is not based on published data but is recommended as a precaution.
In adherence to the protocol of the trial by
Albert et al.,26 we suggest follow-up evaluations
every 3 months, at which time all the initial
screening, including audiography and electrocardiography, should be repeated. The physician
should ask the patient about hearing problems,
disequilibrium, and tinnitus, which might be
signs of ototoxicity. In addition, since any antibiotic can select for Clostridium difficile, the patient
should be asked about diarrhea and other gastrointestinal symptoms.
The cost of generic azithromycin is $99 per
30 doses (www.drugstore.com). Thus, the annual cost of prophylaxis would be $1,188 with
daily azithromycin use or $515 with use three
times weekly. If approximately three patients
need to be treated to prevent one annual exacerbation (as suggested by the results of the
large clinical trial), the annual cost to prevent
an exacerbation would be $3,564 (for daily administration) or $1,545 (for administration three
times a week).

A dv er se Effec t s
There are three major categories of adverse effects that may be anticipated with yearlong use of
azithromycin. These include ototoxicity, cardiac
toxicity, and drug–drug interactions.
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jor concern but one with uncertain clinical implications. In the trial by Albert et al.,26 nasopharyngeal
swabs were obtained for assessment of bacterial
colonization and antibiotic resistance at the time
of enrollment and every 3 months thereafter. The
rates of first-time colonization were lower in the
azithromycin group than in the placebo group, but
the new colonizing organisms were much more
likely to be resistant to macrolide antibiotics (81%,
vs. 41% in the placebo group). The trial was not
large enough and did not have a sufficient duration
to permit an assessment of the clinical consequences of this resistance pattern.
Long-term macrolide prophylaxis has been used
in a number of other disorders. These conditions
include diffuse panbronchiolitis (a chronic inflammatory disease of the bronchioles seen primarily in
Japan, China, and Korea),46-48 cystic fibrosis,49-53
and bronchiectasis.54,55 It has also been used in the
prevention of Mycobacterium avium complex infection in patients with the acquired immunodeficiency syndrome and a CD4+ count below 50 cells
per cubic millimeter.56 In at least some of these
disorders (especially cystic fibrosis), macrolide prophylaxis has been associated with significant
increases in the rate of antibiotic resistance but
without apparent adverse consequences for the
treatment of subsequent acute exacerbations.
A related concern is that of the wider spread
of macrolide-resistant organisms from patients
being treated prophylactically to the general population. In one study, in patients with COPD who
received a macrolide antibiotic within 6 months
after a follow-up culture, the rate of isolation of
S. pneumoniae resistant to a macrolide in sputum
(54%) was nearly four times that in unexposed
controls (14%).57 In theory, close contacts and
family members of patients with antibiotic-resistant strains could acquire the organism.
The wider spread of resistance could also be a
problem for the management of other organisms
for which macrolide antibiotics are used. Azithromycin is commonly administered to treat legionella and mycoplasma infections, but fluoroquinolones are well established as alternative agents for
these pathogens. Of greater concern is the importance of macrolide therapy in the management of
infections with nontuberculous mycobacteria,
which can infect patients with COPD. Some exA r e a s of Uncer ta in t y
perts are promoting the idea of screening patients
The development of antibiotic resistance with pro- with COPD for colonization with nontuberculous
longed azithromycin prophylaxis is an issue of ma- mycobacteria and withholding macrolide prophy-

Hearing loss, disequilibrium, and tinnitus are
potential adverse effects of macrolides.32-34 In the
trial by Albert et al.,26 there was a 5% differential
in hearing loss between the antibiotic-treatment
group (25%) and the placebo group (20%). This 5%
absolute difference is the best estimate of the hearing loss directly attributable to azithromycin with
long-term use. Our review of the literature identified 25 cases of azithromycin-induced ototoxicity.
Some of the patients in these studies were also
taking drugs metabolized by cytochrome P-450,
and in some patients the hearing loss was not reversible during the follow-up period.35-40
Macrolide antibiotics prolong the QTc interval
by blocking a cardiac potassium channel called the
human ether-a-go-go–related gene (HERG) channel.41 A prolonged QTc interval is associated with
an increased risk of torsades de pointes, potentially resulting in ventricular fibrillation and sudden death. In a recent large retrospective cohort
study, short-term use of azithromycin (5 days) was
associated with an estimated 47 additional deaths
from cardiovascular causes per 1 million antibiotic
courses, as compared with amoxicillin.42 Since
torsades de pointes is an unusual event, screening
patients for a QTc interval of more than 450 msec
and excluding them from azithromycin prophylaxis may help minimize the risk (Table 1). Nevertheless, we suggest avoiding the use of azithromycin in patients with a high risk of baseline
cardiovascular disease. Such patients include those
with congestive heart failure, cerebrovascular disease, and peripheral vascular disease.42
Macrolides also inhibit the CYP3A4 isoenzyme, thus increasing serum levels of other
drugs metabolized by this enzyme (Table 1).
Azithromycin is a weaker inhibitor than erythromycin or clarithromycin in vitro,43 but caution is still justified on the basis of individual
variability in CYP3A4 metabolic activity. Examples of drugs with which potentially important
interactions may occur include the statins, resulting in an increased risk of rhabdomyolysis44; warfarin, resulting in an increase in the
international normalized ratio44; and amiodarone, resulting in an increased risk of QTc
prolongation and ventricular arrhythmias.45
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laxis in those with positive sputum cultures (Fennelly K, Griffith D: personal communication). We
concur with this recommendation (Table 1).
The two above-mentioned clinical trials evaluated the effects of a single year of macrolide
prophylaxis, leaving unresolved the question of
whether to continue long-term prophylaxis in
patients with this chronic disease. The experience with long-term macrolide prophylaxis in
patients with other diseases offers some reassurance that azithromycin can be continued after
the first year. We would suggest discontinuing
the drug if important adverse effects surface or
if the number of exacerbations does not decrease
during the first year of treatment. This may be
especially likely among patients with advanced
COPD, whose disease course is typically characterized by an increased number of exacerbations.58
Additional concerns relate to the risk of
known long-term adverse events. Will hearing
loss be additive, and will the rate of this adverse
effect increase? Will QTc-related arrhythmias develop even if patients are carefully selected? Continued screening will be necessary during ongoing prophylaxis. Population-based studies should
be carried out to examine success rates, adverse
drug events, and the effect of antibiotic resistance
after long-term prophylaxis with azithromycin.
It is unknown whether other antibiotics could
be as effective as, or more effective than, azithromycin in patients with COPD. Clinicians treating
pulmonary patients with long-term prophylaxis
have primarily used macrolides. Of the available
macrolides, azithromycin is the most studied and
the one with the fewest adverse effects. Few
other antibiotics have recently been studied for
this purpose. In one trial, patients with stable
COPD were randomly assigned to receive either
moxifloxacin at a dose of 400 mg daily or placebo for 5 days every 8 weeks for 48 weeks. The
mean exacerbation rate was 0.88 with moxifloxacin and 0.94 with placebo, a difference that was
not significant.59 In our view, quinolones should
not be preferred over macrolides for COPD prophylaxis, because they are so important for
treating community-acquired pneumonia.

Guidel ine s
The use of azithromycin for the prevention of
COPD exacerbations has not been endorsed by
current expert guidelines. The GOLD report29
states that “a recent trial of daily azithromycin
showed efficacy on exacerbation end points;
however, treatment is not recommended because
of an unfavorable balance between benefits and
side effects.” A recent update to the American
College of Physicians guidelines28 does not mention the use of prophylactic antibiotics.

R ec om mendat ions
The patient described in the vignette is representative of those with COPD with at least two exacerbations in the previous year. He is knowledgeable about proper inhaler use and is compliant
with his medications. Before prolonged use of
azithromycin is recommended, he should have a
hearing test, electrocardiography to assess his
QTc interval, and a sputum culture for mycobacterial species. If he has no evidence of hearing
impairment and a normal QTc interval, and if the
sputum culture is negative, it is reasonable to
prescribe azithromycin at a dose of 250 mg to be
administered on Mondays, Wednesdays, and
Fridays.
The patient should be followed at 3-month
intervals and should be routinely asked about
the onset of any hearing loss, tinnitus, or disequilibrium. A careful review of all medications
should be carried out to identify any potential
drug–drug interactions. At each 3-month visit,
he should undergo formal audiography and electrocardiography to rule out new hearing issues
or an increased QTc interval, respectively. At the
end of 1 year, he should have a careful reevaluation for adverse effects as well as for evidence of
a reduction in the frequency of COPD exacerbations. If there is clear evidence of benefit, it is
reasonable to consider continuing azithromycin
prophylaxis with appropriate monitoring.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.

References
1. Mannino DM, Homa DM, Akinbami

LJ, Ford ES, Redd SC. Chronic obstructive
pulmonary disease surveillance — United
States, 1971–2000. MMWR Surveill Summ
2002;51(SS-6):1-16.
2. Mathers CD, Boerma T, Ma Fat D.

Global and regional causes of death. Br
Med Bull 2009;92:7-32.
3. Murphy SL, Xu J, Kochanek KD. Deaths:
preliminary data for 2010. Natl Vital Stat
Rep 2012;60(4):1-68.
4. Vestbo J, Edwards LD, Scanlon PD, et

n engl j med 367;4

nejm.org

al. Changes in forced expiratory volume
in 1 second over time in COPD. N Engl J
Med 2011;365:1184-92.
5. Puhan MA, Vollenweider D, Latshang
T, Steurer J, Steurer-Stey C. Exacerbations
of chronic obstructive pulmonary disease:

july 26, 2012

345

The New England Journal of Medicine
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 13, 2015. For personal use only. No other uses without permission.
Copyright © 2012 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

when are antibiotics indicated? A systematic review. Respir Res 2007;8:30. [Erratum, Respir Rev 2008;9:81.]
6. Donaldson GC, Wedzicha JA. COPD
exacerbations. 1. Epidemiology. Thorax
2006;61:164-8.
7. Mittmann N, Kuramoto L, Seung SJ,
Haddon JM, Bradley-Kennedy C, Fitzgerald JM. The cost of moderate and severe
COPD exacerbations to the Canadian
healthcare system. Respir Med 2007;102:
413-21.
8. Berkius J, Nolin T, Mårdh C, Karlström G, Walther SM. Characteristics and
long-term outcome of acute exacerbations
in chronic obstructive pulmonary disease:
an analysis of cases in the Swedish Intensive Care Registry during 2002-2006. Acta
Anaesthesiol Scand 2008;52:759-65.
9. O’Shaughnessy TC, Ansari TW,
Barnes NC, Jeffery PK. Inflammation in
bronchial biopsies of subjects with chronic bronchitis: inverse relationship of
CD8+ T lymphocytes with FEV1. Am J
Respir Crit Care Med 1997;155:852-7.
10. McDonough JE, Yuan R, Suzuki M, et
al. Small-airway obstruction and emphysema in chronic obstructive pulmonary
disease. N Engl J Med 2011;365:1567-75.
11. MacNee W. Pathophysiology of cor
pulmonale in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
1994;150:833-52.
12. Rohde G, Wiethege A, Borg I, et al.
Respiratory viruses in exacerbations of
chronic obstructive pulmonary disease
requiring hospitalization: a case-control
study. Thorax 2003;58:37-42.
13. Sethi S, Murphy TF. Infection in the
pathologies and course of chronic obstructive pulmonary disease. N Engl J Med
2008;359:2355-65.
14. Barnes PJ. The cytokine network in
asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118:354656.
15. Soler N, Ewig S, Torres A, Filelia X,
Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in
patients with stable chronic obstructive
pulmonary disease. Eur Respir J 1999;14:
1015-22.
16. Bresser P, Out TA, van Alphen L, Jansen HM, Lutter R. Airway inflammation
in nonobstructive and obstructive chronic
bronchitis with chronic Haemophilus inf luenzae airway infections: comparison with
noninfected patients with chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 2000;162:947-52.
17. Fagon JY, Chastre J, Trouillet J, et al.
Characterization of distal bronchial microflora during acute exacerbation of
chronic bronchitis: use of the protected
specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir
Dis 1990;142:1004-8.
18. Monsó E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pul-

346

of

m e dic i n e

monary disease: a study of stable and exacerbated outpatients using the protected
specimen brush. Am J Respir Crit Care
Med 1995;152:1316-20.
19. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary
disease (COPD) requiring mechanical
ventilation. Am J Respir Crit Care Med
1998;157:1498-505.
20. Pela R, Marchesani F, Agostinelli C, et
al. Airways microbial flora in COPD patients in stable clinical conditions and
during exacerbations: a bronchoscopic
investigation. Monaldi Arch Chest Dis
1998;53:262-7.
21. Anthonisen NR, Manfreda J, Warren
CPW, Hershfield ES, Harding GK, Nelson
NA. Antibiotic therapy in exacerbations of
chronic obstructive pulmonary disease.
Ann Intern Med 1987;106:196-204.
22. Abu-Gharbieh E, Vasina V, Poluzzi E,
De Ponti F. Antibacterial macrolides: a
drug class with a complex pharmacological profile. Pharmacol Res 2004;50:21122.
23. Martinez FJ, Curtis JL, Albert R. Role
of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3:331-50.
24. Kanoh S, Rubin BK. Mechanisms of
action and clinical application of macrolides as immunomodulatory medications.
Clin Microbiol Rev 2010;23:590-615.
25. Milstone AP. Use of azithromycin in
the treatment of acute exacerbations of
COPD. Int J Chron Obstruct Pulmon Dis
2008;3:515-20.
26. Albert RK, Connett J, Bailey WC, et al.
Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:68998. [Erratum, N Engl J Med 2012;366:1356.]
27. Seemungal TAR, Wilkinson TMA,
Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy
is associated with decreased chronic obstructive pulmonary disease exacerbations.
Am J Respir Crit Care Med 2008;178:113947.
28. Qaseem A, Wilt TJ, Weinberger SE, et
al. Diagnosis and management of stable
chronic obstructive pulmonary disease:
a clinical practice guideline update from
the American College of Physicians,
American College of Chest Physicians,
American Thoracic Society, and European
Respiratory Society. Ann Intern Med
2011;155:179-91.
29. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the
diagnosis, management and prevention of
COPD. 2011 (http://www.goldcopd.org/).
30. Foulds G, Shepard RM, Johnson RB.
The pharmacokinetics of azithromycin in
human serum and tissues. J Antimicrob
Chemother 1990;25:Suppl A:73-82.
31. Retsema JA, Girard AE, Girard D,
Milisen WB. Relationship of high tissue
concentrations of azithromycin to bacte-

n engl j med 367;4

nejm.org

ricidal activity and efficacy in vivo. J Antimicrob Chemother 1990;25:Suppl A:83-9.
32. Williams JD. Evaluation of the safety
of macrolides. Int J Antimicrob Agents
2001;18:Suppl 1:S77-S81.
33. Coulston J, Balaratnam N. Irreversible
sensorineural hearing loss due to clarithromycin. Postgrad Med J 2005;81:58-9.
34. Rubinstein E. Comparative safety of
the different macrolides. Int J Antimicrob
Agents 2001;18:Suppl 1:S71-S76.
35. Tseng AL, Dolovich L, Salit IE.
Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. Clin Infect Dis 1997;24:76-7.
36. Bizjak ED, Haug MT III, Schilz RJ,
Sarodia BD, Dressing JM. Intravenous
azithromycin-induced ototoxicity. Pharmacotherapy 1999;19:245-8.
37. Mamikoglu B, Mamikoglu O. Irreversible sensorineural hearing loss as a
result of azithromycin ototoxicity: a case
report. Ann Otol Rhinol Laryngol 2001;
110:102.
38. Ress BD, Gross EM. Irreversible sensorineural hearing loss as a result of
azithromycin ototoxicity: a case report.
Ann Otol Rhinol Laryngol 2000;109:4357.
39. Wallace MR, Miller LK, Nguyen MT,
Shields AR. Ototoxicity with azithromycin. Lancet 1994;343:241.
40. Brown BA, Griffith DE, Girard W,
Levin J, Wallace RJ Jr. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin
for mycobacterial lung disease. Clin Infect Dis 1997;24:958-64.
41. Volberg WA, Koci BJ, Su W, Lin J,
Zhou J. Blockade of human cardiac potassium channel human ether-a-go-gorelated gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 2002;302:
320-7.
42. Ray WA, Murray KT, Hall K, Arbogast
PG, Stein CM. Azithromycin and the risk
of cardiovascular death. N Engl J Med
2012;366:1881-90.
43. von Rosenstiel NA, Adam D. Macrolide antibacterials: drug interactions of
clinical significance. Drug Saf 1995;13:10522.
44. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin
and dirithromycin. Br J Clin Pharmacol
2000;50:285-95.
45. Samarendra P, Kumari S, Evans SJ,
Sacchi TJ, Navarro V. QT prolongation associated with azithromycin/amiodarone
combination. Pacing Clin Electrophysiol
2001;24:1572-4.
46. Keicho N, Kudoh S. Diffuse panbronchiolitis: role of macrolides in therapy.
Am J Respir Med 2002;1:119-31.
47. Kudoh S, Azuma A, Yamamoto M,
Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchi-

july 26, 2012

The New England Journal of Medicine
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 13, 2015. For personal use only. No other uses without permission.
Copyright © 2012 Massachusetts Medical Society. All rights reserved.

Clinical Ther apeutics
olitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998;
157:1829-32.
48. Park S-J, Lee Y-C, Rhee Y-K, Lee H-B.
The effect of long-term treatment with
erythromycin on Th1 and Th2 cytokines
in diffuse panbronchiolitis. Biochem Biophys Res Commun 2004;324:114-7.
49. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients
with cystic fibrosis chronically infected
with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;
290:1749-56.
50. Wolter J, Seeney S, Bell S, Bowler S,
Masel P, McCormack J. Effect of long term
treatment with azithromycin on disease
parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-6.
51. Hansen CR, Pressler T, Hoiby N, Johansen HK. Long-term, low-dose azithromycin treatment reduces the incidence
but increases macrolide resistance in

Staphylococcus aureus in Danish CF patients.
J Cyst Fibros 2009;8:58-62.
52. Phaff SJ, Tiddens HAWM, Verbrugh
HA, Ott A. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use
in cystic fibrosis. J Antimicrob Chemother
2006;57:741-6.
53. Tramper-Stranders GA, Wolfs TFW,
Fleer A, Kimpen JL, van der Ent CK. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: longterm outcomes related to macrolide
resistance and pulmonary function. Pediatr Infect Dis J 2007;26:8-12.
54. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with
azithromycin. Thorax 2004;59:540-1.
55. Anwar GA, Bourke SC, Afolabi G,
Middleton P, Ward C, Rutherford RM. Effects of long-term low-dose azithromycin
in patients with non-CF bronchiectasis.
Respir Med 2008;102:1494-6.

56. Griffith DE, Aksamit T, Brown-Elliott

BA, et al. An official ATS/IDSA statement:
diagnosis, treatment, and prevention of
nontuberculous mycobacterial diseases.
Am J Respir Crit Care Med 2007;175:367416. [Erratum, Am J Respir Crit Care Med
2007;175:744-5.]
57. Desai H, Richter S, Doern G, et al.
Antibiotic resistance in sputum isolates
of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to
antibiotic exposure. COPD 2010;7:33744.
58. Benfield T, Lange P, Vestbo J. COPD
stage and risk of hospitalization for infectious disease. Chest 2008;134:46-53.
59. Sethi S, Jones PW, Theron MS, et al.
Pulsed moxifloxacin for the prevention of
exacerbations of chronic obstructive pulmonary disease: a randomized controlled
trial. Respir Res 2010;11:10. [Erratum,
Respir Res 2010;11:88.]
Copyright © 2012 Massachusetts Medical Society.

specialties and topics at nejm.org

Specialty pages at the Journal’s website (NEJM.org) feature articles in cardiology,
endocrinology, genetics, infectious disease, nephrology, pediatrics, and many other
medical specialties. These pages, along with collections of articles on clinical and
nonclinical topics, offer links to interactive and multimedia content and feature
recently published articles as well as material from the NEJM archive (1812–1989).

n engl j med 367;4

nejm.org

july 26, 2012

347

The New England Journal of Medicine
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 13, 2015. For personal use only. No other uses without permission.
Copyright © 2012 Massachusetts Medical Society. All rights reserved.

